Search

Displaying results 2121 - 2130 of 3601 in total
  1. Drug

    rPSGL-Ig

    go.drugbank.com/drugs/DB06256
    Investigational

    Recombinant P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a fusion protein of human P-selectin ligand and IgG1-Fc.

    Synonyms: Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig
  2. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  3. Drug

    Avasimibe

    go.drugbank.com/drugs/DB06442
    Experimental

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP3A Inducers
  4. Drug

    Dotarizine

    go.drugbank.com/drugs/DB06446
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Remacemide

    go.drugbank.com/drugs/DB06458
    Experimental

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  6. Drug

    Propentofylline

    go.drugbank.com/drugs/DB06479
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  8. Drug

    P-57AS3

    go.drugbank.com/drugs/DB06569
    Experimental

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  9. Drug

    Nemonoxacin

    go.drugbank.com/drugs/DB06600
    Investigational

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  10. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumo...

    Categories: Receptor Tyrosine Kinase Inhibitors, P-glycoprotein inhibitors